Related Experiment Video
Updated: May 17, 2026
07:32
Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
Published on: May 23, 2025
Metallostasis in Alzheimer's disease
Scott Ayton1, Peng Lei1, Ashley I Bush1
1Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC 3010, Australia.
Free Radical Biology & Medicine
|November 13, 2012
Summary
Alzheimer's disease (AD) research is exploring metal interactions with amyloid-beta (Aβ) as a new therapeutic strategy. Early trials targeting metal dysregulation show promise for AD patients, offering new avenues beyond traditional Aβ approaches.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Multiple large-scale Alzheimer's disease (AD) clinical trials targeting amyloid-beta (Aβ) failed in 2012.
- The increasing social and financial burden of AD necessitates novel therapeutic strategies.
- Previous research focused on Aβ, but recent smaller trials targeting metal interactions with Aβ have shown patient benefit.
Purpose of the Study:
- To review the evidence supporting the metal hypothesis of Alzheimer's disease.
- To explore the role of metal dysregulation in AD pathogenesis.
- To identify potential new therapeutic targets for AD.
Main Methods:
- Review of genetic, pathological, biochemical, and pharmacological evidence.
- Analysis of the role of transition metals (iron, copper, zinc) in AD.
- Examination of the interaction between Aβ, metals, and AD-related proteins (APP, tau, presenilin).
Main Results:
- The AD-affected brain exhibits metallostasis, a disruption in metal trafficking.
- Iron, copper, and zinc play a critical role in AD pathogenesis.
- Proteins like APP, tau, and presenilin are involved in metal regulation and neurodegeneration.
Conclusions:
- The metal hypothesis provides a new framework for understanding AD.
- Targeting metal dysregulation presents a promising therapeutic avenue for AD.
- Further research into metal-protein interactions could lead to effective AD treatments.
More Related Videos
06:41Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
05:54Operation Procedure and Precautions of Thread-Embedding Acupuncture Therapy in Alzheimer
Published on: May 10, 2024
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:03Long-term Depression
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...
Calcium Ion Concentration Mechanism
If over time, all...